Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 378

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 378
---
3.82 | % |     |               | 3.52% to 4.33%         |

F-28

The classification of the fair
value of the earnout liability and derivative liabilities and the change in the fair value measurement using significant inputs (Level
3) for the nine months ended September 30, 2025 (Successor), for the period from January 1, 2024 through February 13, 2024 (Predecessor),
for the three months ended September 30, 2024 (Successor), and for the period from February 14, 2024 through September 30, 2024 (Successor)
for the Company is presented below:

| Preferred stock warrant liability (Predecessor): |     | Level 1 |   |     | Level 2 |   |     | Level 3 |            |   |     | Total |            |   |
|:-------------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-----------:|:--|:----|:------|-----------:|:--|
| Balance at December 31, 2023                     |     | $       | - |     | $       | - |     | $       |    320,117 |   |     |       |    320,117 |   |
| Reclassification of warrant liability to equity  |     |         | - |     |         | - |     |         |   (320,117 | ) |     |       |   (320,117 | ) |
| Balance at February 13, 2024                     |     | $       | - |     | $       | - |     | $       |          - |   |     | $     |          - |   |
| Earnout liability (Successor):                   |     |         |   |     |         |   |     |         |            |   |     |       |            |   |
| Balance at June 30, 2024                         |     | $       | - |     | $       | - |     | $       |    200,000 |   |     | $     |    200,000 |   |
| Gain on revaluation of earnout liability         |     |         | - |     |         | - |     |         |   (170,000 | ) |     |       |   (